Medifast, Inc. (NYSE: MED) — 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual filing, not a standalone fourth-quarter report. Unless indicated otherwise, financial amounts are in U.S. dollars.
Business context and reporting period
Medifast sells weight-management and wellness products primarily through OPTA VIA, a coach-guided, direct-to-consumer program. Its business depends heavily on product sales and its independent Coach network. Product sales generated approximately 97.5% of 2023 revenue. The company began expanding into sports nutrition and medically supported weight loss, including through a collaboration with telehealth provider LifeMD.
Financial performance and liquidity
| Metric | FY 2023 | FY 2022 | Change |
|---|---|---|---|
| Revenue | $1,072.1 million | $1,598.6 million | (32.9%) |
| Gross profit / margin | $775.9 million / 72.4% | $1,140.4 million / 71.3% | Profit down 32.0%; margin up 110 bps |
| Operating income / margin | $126.4 million / 11.8% | $184.8 million / 11.6% | Income down 31.6% |
| Net income | $99.4 million | $143.6 million | (30.8%) |
| Diluted EPS | $9.10 | $12.73 | (28.5%) |
| Cash from operating activities | $147.7 million | $194.6 million | Down $46.9 million |
At year-end, cash and cash equivalents were $94.4 million and investments were $55.6 million, totaling approximately $150.0 million. Working capital was $131.7 million, versus $81.9 million a year earlier. The company had no borrowings under its $225 million revolving credit facility; the facility matures in 2026. Total liabilities were $108.4 million, including lease obligations. Capital expenditures were $6.5 million. Cash dividends paid were $73.0 million in 2023.
At December 31, the Coach network had 41,100 active earning Coaches, down 32.5% from 60,900. Fourth-quarter average revenue per active earning Coach was $4,648, down 16.1% year over year. The filing text does not provide clear standalone fourth-quarter consolidated revenue or profit figures.
Material changes versus the prior comparable period
- Revenue fell primarily due to fewer active Coaches and lower productivity per Coach. Management cited ongoing customer-acquisition pressure.
- Gross margin improved as cost savings and the comparison with 2022 manufacturing restructuring costs partly offset inflation in ingredients, shipping and labor.
- SG&A declined 32.0% in dollars, mainly from lower Coach compensation and expense-reduction efforts, but rose to 60.6% of revenue from 59.8% as lower sales reduced fixed-cost leverage.
- Operating cash flow declined, while cash and investments increased. Investing cash use rose mainly because the company purchased investment securities.
- The company discontinued its quarterly dividend in December 2023 to redirect capital toward growth initiatives.
Outlook, commentary, risks and unusual items
Management describes 2024 as an investment year for marketing, digital customer experience and the LifeMD collaboration. It does not provide numerical financial guidance and does not expect significant operating or revenue effects from these efforts until late 2024, with benefits targeted for 2025 and beyond. The company says it enters 2024 with a strong balance sheet and no debt outstanding.
- Medifast invested $10 million in LifeMD shares and committed up to a further $10 million for collaboration services and infrastructure; $5 million of the latter was paid in 2023, with two $2.5 million payments expected in 2024. The collaboration’s ability to attract and retain customers is uncertain.
- Competition from GLP-1 weight-loss medications is a central business risk, alongside declining Coach counts and revenue per Coach. Other risks include direct-selling regulation, product and advertising claims, supply-chain disruption, inflation, cybersecurity and product liability.
- In the first quarter of 2023, a change to customer terms shifted revenue recognition from customer receipt to delivery to the shipping carrier. The change increased first-quarter 2023 revenue by approximately $9.1 million and operating income by $2.8 million.
- The company ceased Hong Kong and Singapore operations in June 2023. Ordinary-course legal matters were not considered likely to have a material adverse effect, though outcomes remain uncertain. Unrecognized tax benefits were $7.5 million at year-end.
- Auditors issued unqualified opinions on the financial statements and internal control over financial reporting; management also concluded internal controls were effective at year-end.
Most important facts for investors to verify
- Whether active Coach numbers and revenue per Coach stabilize or continue to decline.
- Whether LifeMD and new marketing and digital initiatives produce customer growth, retention and returns commensurate with investment.
- How 2024 investment spending affects operating expenses, cash generation and margins, given the absence of quantified guidance.
- Whether the company sustains liquidity and profitability without dividend payments, and whether its undrawn credit facility remains available on acceptable terms.
- Whether regulatory, healthcare-partnership, product-claim and supply-chain risks result in material costs or operating restrictions.